Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma

Secretory clusterin (sCLU) is expressed in numerous cancers and is associated with the resistance to chemotherapy. However, the role of sCLU in the resistance of hepatocellular carcinoma (HCC) to oxaliplatin (OXA), a recently used third‐generation platinum agent, remains unclear. The stable transfec...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Sci
Hlavní autoři: Xiu, Peng, Dong, Xuesong, Dong, Xiaofeng, Xu, Zongzhen, Zhu, Huaqiang, Liu, Feng, Wei, Zheng, Zhai, Bo, Kanwar, Jagat R., Jiang, Hongchi, Li, Jie, Sun, Xueying
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2013
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657244/
https://ncbi.nlm.nih.gov/pubmed/23279642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12088
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky